Remote strategy-based intervention shows promise for individuals with memory impairments caused by MS

FHS
June 28, 2024
5:10 pm

A pilot study shows promise for a new treatment option for individuals with memory impairments caused by multiple sclerosis (MS).

Axatilimab Shows Efficacy in Recurrent/Refractory GVHD

SAN DIEGO — Axatilimab achieved rapid and durable responses in patients with recurrent/refractory chronic graft-versus-host disease (cGVHD), according to the phase II AGAVE-201 trial. The

December 12, 2023

2024 Could Make or Break Cannabis Stocks

You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter

December 17, 2023

BioArctic-Eisai’s Leqembi gains UAE approval for Alzheimer’s

The treatment is already approved in several other countries, including the US, Japan and China. Credit: David Gyung/Shutterstock. The Ministry of Health and Prevention in

August 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.